Evolent Health Inc (EVH) Director Sells $36,208.00 in Stock
Evolent Health Inc (NYSE:EVH) Director Cheryl Scott sold 1,600 shares of the business’s stock in a transaction that occurred on Monday, June 11th. The shares were sold at an average price of $22.63, for a total transaction of $36,208.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of EVH opened at $23.25 on Wednesday. Evolent Health Inc has a fifty-two week low of $10.30 and a fifty-two week high of $27.25. The company has a market cap of $1.77 billion, a P/E ratio of -33.21 and a beta of 1.14. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.12.
Evolent Health (NYSE:EVH) last announced its earnings results on Wednesday, May 9th. The technology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.06. Evolent Health had a negative net margin of 12.11% and a negative return on equity of 2.16%. The firm had revenue of $139.70 million for the quarter, compared to the consensus estimate of $140.89 million. During the same period in the prior year, the firm earned ($0.14) EPS. The firm’s revenue for the quarter was up 31.5% on a year-over-year basis. research analysts forecast that Evolent Health Inc will post -0.33 earnings per share for the current fiscal year.
A number of equities research analysts have recently issued reports on EVH shares. ValuEngine downgraded shares of Evolent Health from a “sell” rating to a “strong sell” rating in a research note on Monday, April 2nd. Canaccord Genuity reduced their price target on shares of Evolent Health from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Wednesday, February 28th. Zacks Investment Research downgraded shares of Evolent Health from a “hold” rating to a “sell” rating in a research note on Thursday, March 8th. SunTrust Banks boosted their price target on shares of Evolent Health and gave the company a “buy” rating in a research note on Thursday, June 7th. Finally, Wells Fargo & Co reduced their price target on shares of Evolent Health from $27.00 to $20.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 28th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $25.64.
Evolent Health Company Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.